Alexander Testifies In Front of FDA Advisory Committee on Behalf of FCS Patients

Last Updated: Thursday, 10-May-2018 21:15:00 EDT

SILVER SPRING, Md. – National Lipid Association Board Member Lori Alexander, MSHS, RD, CCRC, CLS, FNLA testified on Thursday, May 10 in front of the Food and Drug Administration Endocrinologic and Metabolic Drugs Advisory Committee on behalf of familial chylomicronemia patients. The committee held a hearing regarding the safety and efficacy of a new treatment for FCS, volanesorsen.

"For people with FCS, trying to adhere to an ultra-low to no-fat diet is the only treatment they currently have," Alexander said during her testimony. "Treatment with volanesorsen offers hope to these people, many who have been struggling for years without medical therapy."

Read coverage of the hearing from NLA Media Partner, Rare Disease Report.

Copyright © 2018 National Lipid Association. All Rights Reserved.

Privacy Policy Terms of Service